You are here

Study Evaluating MST-997 in Advanced Malignant Solid Tumors

Last updated on February 22, 2019

FOR MORE INFORMATION
Study Location
New York, New York, 10016 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Neoplasms
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Documented histological or cytological diagnosis confirming the presence of malignant
solid tumor

- Tumor progression after conventional therapy for cancer or a malignant solid tumor for
which no conventional therapy exists

- Subjects enrolled in the MTD confirmation cohort should have a documented histologic
and/or cytologic diagnosis of metastatic breast cancer or non-small cell lung cancer
(NSCLC) and should not have received more than 2 prior chemotherapy regimens for
metastatic disease (adjuvant and neoadjuvant chemotherapy will not be included in the
maximum of 2 prior regimens described above)

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Subjects with symptomatic or clinically active central nervous system (CNS)
metastases. Subjects who have had prior treatment with radiotherapy or surgical
resection for CNS metastases will be permitted if CNS metastases have remained stable
and have not required any treatment for at least 3 months prior to first dose of test
article

- History of any other primary malignancy with less than 5 years documentation of a
disease-free state (Subjects with a history of basal cell or squamous cell carcinomas
of the skin or cervical carcinoma in situ, which have been successfully treated, are
not excluded)

- Recent major surgery (within 14 days before the first dose) or chemotherapy within 28
days before the first dose of MST-997 (42 days if the previous chemotherapy included
nitrosoureas or mitomycin C)

NCT00088647
Pfizer
Terminated
Study Evaluating MST-997 in Advanced Malignant Solid Tumors

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Colorectal Neoplasms, Liver Neoplasms
NCT00143403
All Genders
18+
Years
Multiple Sites
Lung Neoplasms, Non-small Cell Lung Carcinoma
NCT00094094
All Genders
18+
Years
Multiple Sites
Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms
NCT00072748
All Genders

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now